Efficacy and safety of AAV2/5-hRKp.RPGR to treat X-linked retinitis pigmentosa. ESGCT 2017. J. Smith, et al. Poster
Pre-clinical toxicology of AAV2/5-OPTIRPE65, an optimised RPE65 gene therapy vector. ESGCT 2017. A. Georgiadis, et al. Poster
Efficacy assessment and pre-clinical toxicology of AAV2/8-hCARp.hCNGB3, a CNGB3 gene therapy vector. ESGCT 2017. J. Telfer, et al. Poster
Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65. Gene Therapy, 2016. A. Georgiadis, et a.
Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosa. Nature, 2015. B. Pawlyk, et al.
Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Human Molecular Genetics, 2011. L. Carvalho, et al.
Gene therapy reduces Parkinson’s disease symptoms by reorganizing functional brain connectivity. Science Translational Medicine, 2018. Martin Niethammer, et al.
Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease. JCI Insight, 2017. M. Niethammer, et al.
AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. The Lancet, 2011. P. LeWitt, et al.
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson’s disease. PNAS, 2007. A. Feigin, et al.
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. The Lancet, 2007. M. Kaplitt, et al.
